Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.

Advertisement

Related Content

GSK Vaccines: Injecting Visibility
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
Swapping Assets Now Down To Execution For GSK And Novartis
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel